DecisionMap Wealth Management LLC Grows Position in Medtronic PLC $MDT

DecisionMap Wealth Management LLC lifted its position in shares of Medtronic PLC (NYSE:MDT) by 2.9% during the second quarter, Holdings Channel reports. The firm owned 6,287 shares of the medical technology company’s stock after acquiring an additional 180 shares during the period. DecisionMap Wealth Management LLC’s holdings in Medtronic were worth $548,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its stake in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Medtronic by 41.1% in the first quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock valued at $1,427,000 after purchasing an additional 4,626 shares in the last quarter. Nilsine Partners LLC grew its holdings in Medtronic by 6.4% during the 1st quarter. Nilsine Partners LLC now owns 3,203 shares of the medical technology company’s stock valued at $288,000 after buying an additional 194 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Medtronic by 16.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 176,438 shares of the medical technology company’s stock worth $15,855,000 after acquiring an additional 24,777 shares during the period. Finally, Encompass Wealth Advisors LLC bought a new position in shares of Medtronic in the first quarter worth $220,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison bought 2,500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 0.26% of the company’s stock.

Medtronic Trading Up 0.2%

NYSE MDT opened at $95.97 on Tuesday. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $99.37. The stock’s fifty day moving average price is $94.13 and its 200-day moving average price is $89.08. The stock has a market cap of $123.10 billion, a P/E ratio of 26.44, a P/E/G ratio of 2.52 and a beta of 0.78. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date was Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Argus raised their target price on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, August 26th. William Blair raised Medtronic to a “hold” rating in a research note on Friday, July 11th. Mizuho upped their price target on shares of Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Robert W. Baird increased their price objective on Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. Finally, Evercore ISI lifted their target price on shares of Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average price target of $102.82.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.